{
  "id": 5140710,
  "title": "Relay Therapeutics CFO Sells 17,717 Shares for $350,000",
  "url": "https://urgent.news/2026/09/02/relay-therapeutics-cfo-sells-17-717-shares-for-350-000-5140710",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-02T17:00:01.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/coverage/filings/2026/09/02/relay-therapeutics-cfo-sells-17717-shares-for-350000/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Thomas Catinazzo, the Chief Financial Officer of Relay Therapeutics, sold 17,717 shares of the company's common stock on August 14, 2026, according to a filing with the Securities and Exchange Commission. The transaction took place at an average price of $19.74 per share, with a post-transaction value of $19.86 per share based on the market close on that day. Relay Therapeutics is a clinical-stage precision medicine company headquartered in Cambridge, Massachusetts, and employs over 200 people. The company is currently valued at $4 billion. In the past year, Relay Therapeutics' shares have surged by 485%, which has boosted investor confidence in the company's drug development pipeline. As a pre-revenue biotechnology enterprise, Relay Therapeutics' success is contingent on the clinical efficacy and regulatory approval of its small molecule candidates, particularly RLY-4008, which targets unmet medical needs in oncology with unique mechanisms of action.",
  "summary": "Catinazzo's pre-arranged sale reduced his direct stake by 11%, but the insider still holds a significant amount of shares.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Relay Therapeutics CFO Sells 17,717 Shares for $350,000",
        "url": "https://urgent.news/2026/09/02/relay-therapeutics-cfo-sells-17-717-shares-for-350-000",
        "published": "2026-09-02T17:20:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}